Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma.
Katie Rose RyanFrancis GilesGareth J MorganPublished in: European journal of haematology (2020)
The dual inhibition of BET and CBP/EP300 has potential therapeutic benefits for patients with MM.
Keyphrases